SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $1.93M rose 284.1% year over year, ahead of the +122.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 90.3% from the prior quarter. Over 3 fiscal years it compounded at +4.3% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +284.1% holds above the trailing-twelve-month pace of +122.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.93M+90.3% QoQ
Last fiscal yearDec 2025
$1.96M+25.1% YoY
LTMSep 2026
$4.19M+122.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+284.1%——
1 year+25.1%——
3-year CAGR+4.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
1.96M USD
Year-over-year change
+25.1%
4-year CAGR
+17.9%

Stock-Based Compensation vs competitors

How SLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +122.7% is the 3rd highest of 11, against a peer median of +4.3%.
  • Over three fiscal years its annual growth of +4.3% compares with a peer median of +10.1%.
SLS Competitors
Stock-Based Compensation for SLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$187.88M USD-31.7%+9.8%3.2%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$50.41M USD+30.4%+58.3%22.4%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$40.66M USD+8.7%+10.5%5.8%
IMNMImmunome, Inc.LTM Sep 2026$37.41M USD+60.8%+68.9%—
AAPGAscentage Pharma Group InternationalFY2025CN¥20.87M CNY-0.2%-1.9%3.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M USD-43.8%-14.0%46.7%
CBIOCrescent Biopharma, Inc.LTM Mar 2026$16.18M USD+309.7%+51.1%136.2%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$15.73M USD+224.1%+209.1%—
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$10.08M USD-60.8%-22.0%60.3%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$4.19M USD+122.7%+4.3%—
Peer median (excluding SLS) —+4.3%+10.1%15.2%

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Depreciation & Amortization1.27M457K37.87M31.51M0
Deferred Income Tax(239K)(457K)000
Stock-Based Compensation1.01M1.73M1.39M1.56M1.96M
Change in Working Capital(7.62M)5.64M3.35M(6.65M)(4.08M)
Accounts Receivables00000
Inventory00000
Accounts Payables(2.51M)1.21M2.3M(2.14M)(535K)
Other Working Capital(5.1M)4.43M1.04M(4.51M)(3.54M)
Other Non-Cash Items248K10.13M(36.67M)(30.95M)597K
Operating Cash Flow(26.02M)(23.81M)(31.41M)(35.4M)(28.39M)
Capital Expenditures0(4.5M)(5.5M)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(4.5M)(5.5M)00
Debt Repayment00000
Common Stock Issued9.01M23.99M22.23M46.16M86.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.07M85K90K594K(527K)
Financing Cash Flow12.07M24.08M22.32M46.76M86.3M
Effect of Forex Changes00000
Net Change in Cash(13.95M)(4.23M)(14.6M)11.36M57.91M
Free Cash Flow(26.02M)(28.31M)(36.91M)(35.4M)(28.39M)

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.